Fig. 4From: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1AStudy design. Subjects were randomized to one of three treatment arms after a screening period of maximum four weeks. During the treatment period, subjects attended six visits, two of which (dashed line) could be done by telephoneBack to article page